Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tumor Antigen-sensitized DC Vaccine for Colorectal Cancer Liver Metastases
NCT06545630Phase 1Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Nov 2023
- Primary completion
- Nov 2025
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tumor antigen-sensitized dendritic cell vaccine in colorectal cancer (CRC), sponsored by West China Hospital of Sichuan University. Primary endpoint: Disease-free Survival at 18 months. Started Nov 2023; status: recruiting.
02
Drugs
tumor antigen-sensitized dendritic cell vaccine
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06545630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06545630.